



Article

Subscriber access provided by UB + Fachbibliothek Chemie | (FU-Bibliothekssystem)

Scope and Limitations of the Liebeskind-Srogl Cross-Coupling Reactions Involving the Biellmann BODIPY

Lourdes Betancourt-Mendiola, Ismael Valois-Escamilla, Teresa Arbeloa, Jorge Bañuelos, Iñigo Lopez Arbeloa, Juan Orlando Flores-Rizo, Rongrong Hu, Erik Lager, Cesar Fernando Azael Gómez-Durán, José Luis Belmonte-Vázquez, Mayra Rosario Martínez-Gonzalez, Ismael Javier Arroyo, Carlos Alberto Osorio-Martinez, Enrique Alvarado-Martínez, Arlette Urías-Benavides, Brenda Daniela Gutierrez-Ramos, Ben Zhong Tang, and Eduardo Peña-Cabrera

> J. Org. Chem., Just Accepted Manuscript • Publication Date (Web): 12 May 2015 Downloaded from http://pubs.acs.org on May 12, 2015

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



The Journal of Organic Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Scope and Limitations of the Liebeskind-Srogl Cross-Coupling Reactions Involving the Biellmann BODIPY.

Lourdes Betancourt-Mendiola,[†] Ismael Valois-Escamilla,[†] Teresa Arbeloa, [¥] Jorge Bañuelos,^{*, ¥} Iñigo López Arbeloa,[¥] Juan O. Flores-Rizo,[†] Rongrong Hu,[‡] Erik Lager,[†] César F. A. Gómez-Durán,[†] José L. Belmonte-Vázquez,[†] Mayra R. Martínez-González,[†] Ismael J. Arroyo,[†] Carlos A. Osorio-Martínez,[†] Enrique Alvarado-Martínez,[†] Arlette Urías-Benavides,[†] Brenda D. Gutiérrez-Ramos,[†] Ben Zhong Tang,[‡] and Eduardo Peña-Cabrera^{*,†}

[†] Departamento de Química, Universidad de Guanajuato, Col. Noria Alta S/N, Guanajuato, Gto. 36050 Mexico.

^{*} Departamento de Química Física, Universidad del País Vasco-EHU, Apartado 644,
48080, Bilbao, Spain.

[‡] Department of Chemistry, The Hong Kong University of Science & Technology, Clear Water Bay, Kowloon, Hong Kong, China.

E-mail: eduardop@ugto.mx, jorge.banuelos@ehu.es

Abstract

Several new examples of *meso*-(het)arylBODIPY were prepared via the Liebeskind-Srogl (L-S) cross-coupling reaction of the Biellmann BODIPYs (**1a,b**) and aryl- and heteroarylboronic acids in good to excellent yield. It was shown that this reaction could be carried out under microwave heating shortening reaction times and/ or increasing the yield. It was illustrated that organostannanes also participate in the L-S reaction to give the corresponding BODIPY analogues in short reaction times and also with good to excellent yields. We analyze the role of the substituent at the sensitive *meso* position in the photophysical signatures of these compounds. In particular, the rotational motion of the aryl ring and the electron donor ability of the anchored moieties rule the non-radiative pathways, and hence have a deep impact in the fluorescence efficiency.

Introduction

Truly remarkable applications of dipyrromethene- BF_2 fluorophores 1 (BODIPYs[®])¹ continue to appear in the literature. These fluorescent compounds were first reported by Treibs and Kreuzer in 1968.² Little did they know about the great impact these analogues were to have in so many disciplines. The properties of this family of compounds are reported in excellent reviews.³



Some relevant examples of their applications include the tagging of biomolecules,⁴ as components of supramolecular light-harvesting systems,⁵ in the construction of dye

ACS Paragon Plus Environment

sensitized solar cells,⁶ as sensors,⁷ as components of fluorescent nanocars,⁸ as nanoparticle conjugates,⁹ as ligands for human β -adrenoceptors,¹⁰ as components of bulk heterojunction solar cells,¹¹ in real-time PCR methods,¹² and to visualize Langerhans islets,¹³ and as a quality control in milk,¹⁴ among others.

Assorted methods exist in the literature dealing with the functionalization of the BODIPY 1-7 positions.¹⁵ The importance of *meso*-substituted bodipy analogues was pointed out by Nagano *et al.*¹⁶ They considered the bodipy general structure as a two-component entity (Figure 1), the bodipy portion (in red) as the fluorophore and the aryl moiety (in blue) as the fluorescent switch, that regulates the quantum yields, at least in the 1,7-dimethylbodipy derivatives.

FIGURE 1. Roles of the fragments of a *meso*-arylsubstituted BODIPY.



Additionally, the *meso* position is the most sensitive to substituents effects because, upon excitation, an important variation in the electron density takes place at that site.¹⁷ From the strategic point of view, the *meso* position is arguably the most important because in the majority of the applications that have been devised for BODIPYs, it is the position of choice for the attachment of the substrate to study.¹⁸

In the initial contribution of this laboratory,¹⁹ we reported a mild method that allowed the introduction of a series of functional groups at the *meso*-position via the Liebeskind-Srogl (L-S) cross-coupling²⁰ *under neutral conditions* (Scheme 1). The key component of such process was 8-methylthioBODIPY **1a**, henceforth termed the Biellmann BODIPY.²¹ The

structures of the BODIPY analogues prepared by this methodology (**2-20**) are shown in Chart 1.

SCHEME 1. Application of the Liebeskind-Srogl cross-coupling in the synthesis of *meso*-substituted BODIPY analogues using the Biellmann BODIPY 1.



In that contribution, the advantages of this methodology over the typical acid-catalyzed condensation of an aldehyde and an excess amount of pyrrole (the Lindsey²² conditions) method were pointed out. Summarizing, the main shortcomings of the Lindsey methodology include: a separate synthesis of the starting aldehyde if it is not commercially available, cumbersome purifications, incompatibility of the substituents on the het(aryl) ring of the aldehyde to acidic conditions, oxidation, and strong Lewis-acid exposure (BF₃).

Chart 1





In two further contributions that demonstrated the usefulness of boronic acids as partners in the L-S cross-coupling, derivatives of the type **21-24** were prepared.²³

We have also demonstrated that the Biellmann BODIPY **1** engages in a desulfitative reduction to give the parent unsubstituted BODIPY dye,²⁴ in S_NAr -like processes to displace the 8-methylthio group by amines,²⁵ phenols and alcohols,²⁶ and *C*-centered soft nucleophiles.²⁷ In a recent contribution, we have shown that carbohydrate-BODIPY hybrids could be prepared in a one-pot sequence that entailed a L-S cross-coupling followed by a copper-catalyzed azide-alkyne reaction.²⁸

We wish to disclose herein a more in-depth study of the scope and limitations of the Biellmann BODIPY as participant in cross-coupling reactions leading to the synthesis of *meso*-substituted BODIPY dyes, as well as the optical data of selected examples prepared by this methodology. We seek to demonstrate that both the Biellmann BODIPYs **1a** and its alkylated analogue **1b** are privileged starting materials for the efficient and straightforward preparation of assorted BODIPY derivatives. The advantages of this process are more relevant since both **1a**, and **1b** are now commercially available.

Results and Discussion

Cross-Couplings with Boronic Acids. Following the reaction conditions showed in Scheme 1, derivatives **25-47** were prepared (Chart 2).







^a Isolated yields. **1a** or **1b** (1 equiv), boronic acid (3 equiv), CuTC (3 equiv), Pd₂(dba)₃ (2.5 mol%), TFP (7.5 mol%), THF (3 mL).

Similarly to the results observed in our first contributions,^{19,23b} the LS cross-coupling reaction of the Biellmann BODIPYs 1a,b with a greater variety of aryl- and heteroarylboronic acids continued giving excellent results. The electronic nature of the arylboronic acids does not affect either the reaction time or the chemical yields. Arylboronic acids with either electron-releasing or electron-withdrawing groups react very smoothly to produce the expected products in good yields. Sterically demanding boronic acids efficiently reacted as well (28, 34, 37, 38, 39, 43, 44, 45). Arylboronic acids with reactive functional groups smoothly reacted to produce the desired products, i.e., compounds 32, 33 and 45 without having to protect them. Heteroarylboronic acids that are known to protodeboronate under Suzuki conditions,²⁹ reacted efficiently under the neutral LS cross-coupling reaction conditions to yield compounds 15, 16, 37, 39, and in good yields and short reaction times. The family of halogen-containing BODIPYs initially reported (10, 11, 12, and 22) was now extended to analogues that contain Br, I and Cl with different substitution patterns that could be further elaborated via transitionmetal catalyzed reactions (26, 27, 28, 29, 31, and 38). Of particular interest is the straightforward preparation the formylaryl derivatives 40 and 44 in 88 and 93% yield, respectively. If one wanted to prepare 40 using the traditional Lindsey method, several steps involving protections and deprotections would be needed³⁰ (Scheme 2). On the other hand, the same compound could be prepared in a single and efficient operation via the L-S cross-coupling.

SCHEME 2. Synthesis of 40 using the Lindsey method.



Compound **44**, however, would be lengthy at best to prepare using the Lindsey method because it would imply the monoprotection of 4-methoxy-isophthalaldehyde (eq 1) with its inherent regioselectivity issues.



The numerous examples of commercially available formyl-containing arylboronic acids allows for the preparation of as many BODIPY derivatives and their possible applications in areas such as dye-sensitized solar cells,^{29c} the construction of energy transfer cassettes,^{29b} and cysteine and homocysteine sensors.³¹ 4-Aminomethylphenylboronic acid failed to yield the desired product **47**, presumably because the nucleophilic amino group displaced the MeS group in **1a** faster than the L-S reaction took place.²⁴ This drawback was not observed in the case of 3-aminophenylboronic acid to give **25** due to the reduced nucleophilicity of the nitrogen atom in aromatic amines. A similar phenomenon may have taken place to prevent the formation of **41**. We recently reported the fast transthiolation of **1a** in the presence of arylthiols in THF.³²

L-S Cross-Couplings Under Microwave Irradiation. We then decided to explore the efficiency of the microwave irradiation. Thus, a short survey was carried out (Table 1).

Table 1. L-S Cross-Couplings with Boronic Acids Under Microwave Irradiation



Entry	Ar	Time	% yield ^a μw heating	Time	% yield thermal heating	Cmpd
1	ОН	5 min	95	1 h	96	33
2	Br	30 min	85	70 min ^b	83 ^b	12
3	Cl	20 min	90	1 h	86	31
4		10 min	92	5 h ^b	79 ^b	4
5	OMe	5 min	91	30 min ^b	76 ^b	8

^a Isolated yields. **1a** (1 equiv), boronic acid (3 equiv), CuTC (3 equiv), Pd₂(dba)₃ (2.5 mol%), TFP (7.5 mol%), THF (3 mL) in a sealed vessel. ^b Data taken from ref. 18.

Table 1 shows that the L-S cross-coupling reaction is quite compatible with the microwave heating regime. In all the cases studied, the reaction times shortened significantly. Although the yields in entries 1 and two remained the same, those of entries 3-5 increased. Overall, carrying out the L-S coupling under microwave heating proved advantageous.

Cross-Couplings with Organostannanes. Since organostannanes also participate in the L-S cross-coupling,³³ it was decided to compare their reactivity against that observed with boronic acids.

Initial testing of the typical L-S reaction conditions $(Pd_2(dba)_3, TFP, Cu(I)TC, THF, 55 °C)$ for the coupling of **1a** with organostannanes, led to incomplete conversions even after 3 days. One attempt to accelerate the reaction in the presence of one equivalent of CsF^{34} failed, only decomposition of **1a** was observed. The catalytic system was changed to Pd(PPh₃)₄, which resulted in a rather complex reaction mixture. We then decided to use the conditions reported by Guillaumet *et al.*³⁵ for similar reactions. The results are shown in Table 2.

Table 2. Survey of the Reactivity of Organostannanes in the Liebeskind-Srogl Cross-Coupling Using the Guillaumet Conditions.

SMe		CuBr •SMe ₂	Ar
	+ Ar -SnBu ₃	\sim 5% Pd(PPh ₃) ₄	
1a		THF, 55 °C	1 1

Entry	Ar	time (h)	Compd.	% yield ^a
1	<i>p</i> -CH ₃ OC ₆ H ₄ -	49	8	52
2	<i>p</i> -CH ₃ C ₆ H ₄ -	50	36	75
3	p-ClC ₆ H ₄ -	22	31	79
4		52	48	52
5	C ₆ H ₅ -	46	2	52

^a Isolated yield. BODIPY **1a** (1 equiv), ArSnBu₃ (3 equiv), CuBr•SMe₂ (3 equiv), Pd(PPh₃)₄ (5 mol%), THF (5 mL).

Although the products were obtained in moderate to good yields, the reactions in all of the cases analyzed were very sluggish taking up to 50 h to go to completion.

Since the results were not quite satisfactory, we turned our attention to studying the outcome of the reaction using copper (I) diphenylphosphinate, Cu(I)OP(O)Ph₂, as the Cu source, since it has been demonstrated that it gives good results in similar cross-coupling with organostannanes.^{33a} The results are shown in Table 3.

Table 3. Survey of the Reactivity of Organostannanes in the Liebeskind-Srogl **Cross-Coupling Using Cu(I) Phosphinate as Cu(I) Source.**

	SMe N = + Ar-SnBu F F F 1a	CuOP 3	(O)Ph ₂ (PPh ₃) ₄ 55 °C	Ar N.B.N. F.F
Entry	Ar	time (h)	Compd.	% yield ^a
1	<i>p</i> -CH ₃ OC ₆ H ₄ -	1.0	8	85
2	<i>p</i> -CH ₃ C ₆ H ₄ -	0.5	36	77
3	$p-ClC_6H_4-$	0.5	31	81
Λ		0.5	40	75

 $\frac{5}{\text{a Isolated yield. BODIPY 1a (1 equiv), ArSnBu₃ (3 equiv), CuOP(O)Ph₂ (3 equiv),}}$ Pd(PPh₃)₄ (5 mol%), THF (3 mL).

Gratifyingly, the reaction times in all cases surveyed dropped to one hour or less and the yields increased significantly irrespective of the electronic properties of the aryl groups, at least in the group studied.

Photophysical properties. The spectroscopic properties of selected meso-(het)arylBODIPY derivatives listed in Chart 1 and 2 are collected in Table 4.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
30
37
38
39
40
41
4∠ ∕\?
43
44 ⊿5
40 76
40 ⊿7
47 ∕12
40 40
50
51
52
53
54
55
56
57
58
59
60

Table 4.	Photophysical Properties of Selected BODIPYs in tetrahydrofurane;
absorption	(λ_{ab}) and fluorescence (λ_{fl}) wavelengths, and fluorescence quantum yield
(Φ). The c	omplete photophysical data of compounds listed in Chart 2 are collected
in Table S1	l in ESI.

Cmpd	λ_{ab}	λ_{fl}	%Φ	Cmpd	λ_{ab}	λ_{fl}	%Φ ^a
	(nm)	(nm)			(nm)	(nm)	
2	501	520	2.6	27	514	533	6.3
3	499	520	1.1	28	518	535	55.0
4	373, 502	524	1.0	29	502	522	0.7
5	493	532	5.3	30	500	519	1.0
6	502	527	0.4	31	502	521	0.7
7	501	524	2.4	32	514	535	2.9
8	498	520	3.5	33	499	516	1.5
9	494	533	0.7	34	516	528	25.0
10	502	527	1.1	35	512	526	5.2
11	504	529	1.3	36	500	516	3.6
12	507	527	29.5	37	517	528	55.4
13	505	533, 622	2.3	38	508	528	8.7
14	506	-	-	39	520	533	35.0
15	510	620	2.9	40	516	541	1.7
16	417, 520	583	-	42	512	529	9.7
17	507	525	13.5	43	502	520	51.0
18	387, 501	524	0.6	44	505	522	43.0
19	503	530	-	45	500	515	87.8
20	506	539	0.5	46	514	-	-
25	511	526	0.3				
26	502	522	1.3				

^a Concentration: 20 µM

The presence of a phenyl ring at *meso* position of the BODIPY **2** has little impact in the absorption spectra due to the absence of resonance interaction. In fact, the 8-phenyl group does not contribute to the electronic density of the frontier molecular orbitals involved in the electronic transition.¹⁷ Moreover, the functionalization of such ring scarcely shifts the absorption band (centered around 500-505 nm, Table 4), although electron donors (i.e., amine in **9** and methoxy in **3** and **8**) or acceptors (i.e., halogens in **10-12** or **29** and

carboxylates in **32** and **43**) have been grafted to different positions of the 8-phenyl. Just a slight bathochromic shift (10-15 nm, Table 4) is recorded in the absorption band owing to the direct attachment of electron donor heteroaryls (thiophene in **15** and **46** or furane in **16**) to the *meso* position of the BODIPY, which might indicate some degree of electron coupling with the cyanine-like delocalization of the chromophoric core. Overall, absorption bands at lower energies (centered around 510-520 nm, Table 4) are recorded for the diethylated compounds in the 3 and 5 positions (see compounds **25-28**, **32**, **34**, **35**, **37**, **39**, **40**, **42** and **46** form Chart 2) due to the positive inductive effect of the alkyl groups especially in those chomophoric α -positions, as will be emphasized later.

Nonetheless, the arylation of the *meso* position plays a fundamental role in the emission signatures (mainly in the fluorescence efficiency) of the herein attained compounds (Table 4). As a matter of fact, those compounds in which the aryl ring can easily rotate due to the lack of substituents at neither adjacent 1 and 7 positions of the BODIPY core nor at the *ortho* positions of the 8-aryl moiety (compounds 2-20, except 12 and 17 from Chart 1, and 25-27, 29-33, 35-36, 40, 42 and 46 from Chart 2) are characterized by very low fluorescence efficiency (< 10%, Table 4). The rotational motion of the aryl at *meso* position greatly enhances the vibrational coupling with the BODIPY chromophore and eventually can distort its planarity. Both factors result in an increase in the non-radiative relaxation pathways.³⁶ The fluorescence efficiency is worsened by the additional presence in the aryl ring of strong electron donating or withdrawing groups which enable fluorescence-quenching intramolecular charge transfer (ICT) processes. For instance, the emission becomes almost negligible in compounds 14 and 25 (Table 4), both of them bearing electron releasing groups (ferrocene and amino, respectively) which are known to

be capable of promoting such kind of phenomena. Moreover, in derivatives **13**, **15** and **16** even a weak emission from the ICT is detected at long wavelengths, especially with pyrene and thiophene, as it is show in Figure 2. Indeed, in compound **13** a dual emission is clearly detected; the fluorescence from the locally excited (LE) state and the fluorescence from the ICT state, which is populated from such LE (Figure 2). The replacement of pyrene by the more electron donor thiophene (**15**) leads to the complete quenching of the emission from the LE, and just the long wavelength emission from the ICT is detected, albeit quite weak. It is noteworthy that such red-shifted emission recorded for compound **15** is not longer detected when a phenyl ring is fused to the 8-thiophene **46**, which results in a completely loss of the fluorescence signal. Likely, the charge separation is further favoured increasing the non-radiative deactivation from the ICT state.



Figure 2. Fluorescence spectra of compounds 2 (8-phenyl), 13 (8-pyrene) and 15 (8-thiophene).

As stated above, ethylation at the key chromophoric α -positions not only bathochromically shifts the spectral bands, but also counteracts in part the above

commented internal conversion promoted by the unconstrained 8-aryl groups. Thus, comparing the analogs bearing the trimethylsilyl group (30 vs 42) an improvement in the fluorescence efficiency is attained upon alkylation (from 1% to 9.7% respectively, Table 4). The same trend is nicely observed in the BODIPYs bearing brominated phenyls at different positions (non alkylated 10, 11 and 12 vs 26, 27 and 28 ethylated at positions 3 and 5). Such improvement is attributed to an enhancement in the electronic delocalization by the insertion of inductive electron donor alkyl groups at the α -positions of the cyanine π -system.³⁶ In fact the highest molar absorption coefficients (around 90000- 100000 M⁻¹ cm⁻¹ in Table S1 in ESI) are calculated for alkylated compounds (i.e., **25**, **27**, **35** and **42**). In contrast, the *ortho* substitution of the arvl ring reverses the situation and bright BODIPYs are attained (Table 4). Figure 3 shows that whereas for the aforementioned derivatives with unconstrained 8-aryl and hence low fluorescence quantum yields, the lifetimes were very fast (multiexponentials with main lifetime below 1 ns, see Figure 3 and Table 1 in ESI), the steric hindrance provided by the *ortho* substitution not only raises up the fluorescence efficiency but also lengthens the lifetime (monoexponentials with values around 3-6 ns, those typical of BODIPY, see Figure 3 and Table 1 in ESI) owing to the restriction of the aryl free motion. Indeed, among the compounds in Chart 1, the highest fluorescence quantum yield is recorded for compound 12 (29.5% in Table 4) bearing an ortho-brominated 8-phenyl fragment, while its brominated analogs at *para* or *meta* positions (10 and 11, respectively) show much more reduced fluorescence efficiencies (1.1% and 1.3%, Table 4). Nicely, the selective bromination of the phenyl ring leads to the same trend in derivatives 26-28 from Chart 2, but with ameliorated fluorescence efficiencies due to the aforementioned alkylation effect. Moreover, in Chart

2 all the *ortho* substituted derivatives (**34**, **37-39** and **43-45**) provide the highest fluorescence efficiencies, which reach values as high as 87.8% for compound **45** (Table 4), and longer lifetimes (grey shaded in Figure 3).



Figure 3. Fluorescence lifetime of selected BODIPY listed in Chart 2 with *ortho*susbtitution (grey) and without substitution (white) at such position of the 8-aryl. For the last set of compound the main lifetime (contribution > 98%) is provided due to the biexponential deconvolution of the decay curve.

All this background prompted us to analyzed the rotational barrier of the 8-phenyl in BODIPYs where is motion is readily free (compound **31** was chosen as representative) or progressively hindered by steric hindrance due to the *ortho* substitution of the aryl groups (**38** and **45**, those with the smallest and highest fluorescence efficiency among these kind of derivatives). Such theoretical potential energy surface was computed scanning and relaxing the energy with regard to the dihedral angle between the phenyl and the indacene core planes using Molecular Mechanics (MM2) (some representative curves are depicted in Figure 4) and the Density Functional method (DFT, in particular B3LYP, see experimental section for further details). As expected, the lowest rotational barrier is calculated for compound **31** (13.2 kcal/mol by MM2, Figure 4, and 10.0 kcal/mol by

DFT), where the most stable conformation is with the phenyl ring twisted around 52° with respect to the indacene core.. The presence of a fluorine atom at *ortho* position in **38** hinders the phenyl motion as reflected in a higher rotational barrier (18.6 kcal/mol by MM2, Figure 4, and 15.7 kcal/mol by DFT) and a higher twisting angle (60°). However, owing to its small size the steric hindrance seems not to be high because its fluorescence efficiency is still low (8.7%, Table 4). Further evidence is provided by compound 12 bearing an *ortho*-bromine. Its larger size should induce a higher steric hindrance to the phenyl motion, reflected in a higher rotational barrier (28.1 kcal/mol by MM2 and 25.1 kcal/mol by DFT) and a more twisted 8-phenyl (65°), which leads to an improved fluorescence signal (29.5% Table 4). In line with this argument, compound 45 shows a larger rotational barrier (around 35 kcal/mol by MM2 and 37.6 by DFT) and a more perpendicular disposition (phenyl twisted 70°). Thus, the geometrical constraint provided by the hidroxymethylene seems to be high enough to lock the phenyl ring motion, thereby giving rise to very high fluorescence efficiencies (up to 87.8%, Table 4). Alike energy values have been reported for the rotational barrier of structural related 8-aryl-BODIPYs.³⁷ It is noteworthy that the low-demanding (from a computationally point of view) and fast MM2 method, describes qualitatively way the evolution of the rotational barrier with regard to the steric hindrance induced by the *ortho* substitution, although the energy values deviate around 3 kcal/mol (usually MM2 overestimates the barrier) with regard to the more accurate DFT method.



Figure 4. Energy potential surface with regard to the rotation of the 8-aryl fragment by MM2 method for representative compounds 31 and 38.

Therefore, constrained structures are required to keep the excellent fluorescence signal from the BODIPY. Nevertheless, those derivatives bearing 8-aryl with free motion are being applied in the emerging field of molecular rotors to monitor the environmental viscosity owing to the sensibility of both the fluorescence efficiency and lifetime to the ring rotation.³⁸ The herein presented set of derivatives could be applied as such kind of probes with the additional advantage that the functionalization of the 8-aryl group (*i.e.*, halogens, carboxylic acids) enables subsequent synthetic modification to improve for instance the biological compatibility or to seek for a specific target.

Conclusions

A detailed study has been carried out regarding the scope and limitations of the Biellmann BODIPY as the electrophilic partner in the Liebeskind-Srogl cross-coupling reaction. Several highly substituted aryl- and heteroarylboronic acids were tested to give the desired products in short reaction times and good to excellent yields. The only observed limitations were in cases where the boronic acids contained nucleophilic groups (i.e., NH₂ and SH groups) for in those cases, the reaction failed to yield the expected

product. It was also demonstrated that the L-S cross coupling reaction works efficiently using microwaves, giving the products in higher yields, or shorter reaction times, or both. In addition to boronic acids, we showed that organostanannes were also effective partners in the L-S cross coupling reaction with the Biellmann BODIPY. It is envisioned that this methodology will be highly favored by the chemistry community interested in BODIPY dyes due to all of the advantages it presents, as well as to the fact that Biellmann BODIPYs are commercially available. The functionalization at the key *meso* position severely alters the fluorescence signatures of the BODIPY. Bulky substituents at the *ortho* position of 8-aryl groups are required to provide high enough steric hindrance, as reflected in higher rotational barriers, to lock the ring rotational motion and ensure high fluorescence efficiencies, which can be further boosted by alkylation at positions 3 and 5. Alternatively, the electron coupling of electron releasing groups at the 8 position of BODIPY promotes ICT states with long-wavelength emission, but with the handicap of its inherent low fluorescence efficiency.

Experimental Section

Synthesis and characterization: All of the starting materials were purchased from commercial sources and used without further purification. ¹H and ¹³C NMR spectra were recorded spectrometer in deuteriochloroform (CDCl₃), with either tetramethylsilane (TMS) (0.00 ppm ¹H, 0.00 ppm ¹³C), or chloroform (7.26 ppm ¹H, 77.00 ppm ¹³C), as internal reference. Data are reported in the following order: chemical shift in ppm, multiplicities (br (broadened), s (singlet), d (doublet), t (triplet), q (quartet), sex (sextet), hep (heptet), m (multiplet), exch (exchangeable), app (apparent)), coupling constants, *J* (Hz), and integration. Infrared peaks are reported (cm⁻¹) with the following relative

The Journal of Organic Chemistry

intensities: s (strong, 67–100 %), m (medium, 40–67%), and w (weak, 20–40%). HRMS were recorded as specified. Melting points were determined on the appropriate equipment and are not corrected. TLC was conducted in Silica gel on TLC Al foils. Detection was done by UV light (254 or 365 nm). The reactions with microwave heating were carried out on a CEM Discover SP reactor with a vertical IR focalized internal temperature sensor. Mass spectrometry data were collected on a TOF analyzer.

Spectroscopic measurements. The photophysical properties were registered in diluted solutions (around 2×10^{-6} M) of tetahydrofurane, using quartz cuvettes with optical pathway of 1 cm. UV-Vis absorption and fluorescence spectra were recorded on a spectrophotometer and a spectrofluorimeter, respectively. Fluorescence quantum yield (Φ) was obtained by using a suitable commercial BODIPY as reference (PM567 in methanol $\Phi = 0.91$). Radiative decay curves were registered with the time correlated single-photon counting technique , equipped with a microchannel plate detector of picosecond time-resolution (20 ps). Fluorescence emission was monitored at the maximum emission wavelength after excitation at 470 nm by means of a diode laser with 150 ps FWHM pulses. The fluorescence lifetime (τ) was obtained after the deconvolution of the instrumental response signal from the recorded decay curves by means of an iterative method. The goodness of the exponential fit was controlled by statistical parameters (chi-square, Durbin-Watson and the analysis of the residuals). The amplitude average lifetime was calculated by means of $z < \tau >_{aa} = \Sigma A_i \cdot \tau i$

Computational modeling. Ground state energy minimizations were performed using the Becke's Three Paramaters (B3LYP) Density Functional (DFT) method. The basis set was the double valence 6-31g, except from those compounds bearing iodine (*i.e.*, **38**) where

the lanl2dz basis set, especially parameterized for such heavy atoms, was considered. The optimized geometry was taken as an energy minimum using frequency calculations (no negative frequencies). Rotational energy barriers were calculated from the potential energy surface, which was simulated by relaxed scans of the 8-phenyl twist with regard to the plane of the BODIPY core. Two complementary approaches were considered to this aim. First, the relaxed scans were carried out using the MM2 force field as implemented in ChemBio 3D Ultra (ChemBioOffice 2014 software). The resolution of the scan was 1°. Finally, the potential surface was simulated by the B3LYP method computing and minimizing the energy in steps of 10°. The solvent effect (tetrahydrofuran) was considered in the DFT calculations by the Polarizable Continuum Model (PCM), except for compound **38**, where the calculations were done at gas phase, since the iodine atom is not parameterized in PCM. All the DFT calculations were performed in Gaussian 09, using the "arina" computational resources provided by the UPV-EHU.

General procedure for the L-S cross-coupling with boronic acids (GP1). A Schlenk tube equipped with a stir bar was charged with a either 1a or 1b (1 equiv), the corresponding boronic acid (3 equiv), and dry THF (3 mL). The mixture was sparged with N₂ for 5 min whereupon Pd₂(dba)₃ (2.5 mol%), trifurylphosphine (7.5%), and CuTC (3 equiv) were added under N₂. The Schlenk tube was then and immersed in a pre-heated oil-bath at 55 °C. The oil-bath was removed after the starting BODIPY was consumed (TLC, 20% EtOAc/hexanes) (see Chart 2 for reaction times). After the mixture reached rt, the crude material was adsorbed in SiO₂-gel and the product was purified by flash

The Journal of Organic Chemistry

chromatography on SiO₂-gel using EtOAc/hexanes gradients. For purposes of characterization, the products were crystallized from CH_2Cl_2 /petroleum ether.

BODIPY 25. According to GP1. **1b** (30.0 mg, 0.102 mmol), 3-aminophenylboronic acid (47.4 mg, 0.306 mmol), Pd₂(dba)₃ (2.4 mg, 2.6 x10⁻³ mmol), TFP (1.8 mg, 7.6 x10⁻³ mmol) and CuTC (58.3 mg, 0.306 mmol). The desired product (26.2 mg, 90%) mmol) was obtained as orange crystals. TLC (30% EtOAc/hexanes, $R_f = 0.46$); mp 176-177 °C; IR (KBr, cm⁻¹): 3495 (m), 3466 (m), 3399 (m), 3377 (m), 2927 (m), 1556 (s), 1432 (s), 1284 (s), 1150 (s), 1031 (s), 998 (s), 950 (s), 800 (s); ¹H NMR (200 MHz, CDCl₃): δ 7.21 (d, *J* = 8.0 Hz, 2H), 6.89-6.80 (m, 4H), 6.33 (d, *J* = 4 Hz, 2H), 3.79 (bs, 2H), 3.07 (q, *J* = 8.0 Hz, 4H) 1.34 (t, *J* = 8.0 Hz, 6H); ¹³C NMR (50 MHz, CDCl₃): δ 163.3, 146.1, 143.2, 135.2, 134.2, 130.5, 129.0, 120.9, 117.1, 116.7, 116.4, 22.0, 12.8. HRMS FABS (M+H⁺) Calcd for C₁₉H₂₁BF₂N₃: 340.1796. Found: 340.1799.

BODIPY 26. According to GP1. **1b** (30.0 mg, 0.102 mmol), *p*bromophenylboronic acid (62.0 mg, 0.306 mmol), Pd₂(dba)₃ (2.4 mg, 2.6 x10⁻³ mmol), TFP (1.8 mg, 7.6 x10⁻³ mmol), and CuTC (58.3 mg, 0.306 mmol). The desired product (23.4 mg, 58%) was obtained as red crystals. TLC (15% EtOAc/hexanes, $R_f = 0.64$); mp 135-136 °C; IR (KBr, cm⁻¹): 2977 (w), 2941 (w), 1571 (s), 1554 (s), 1488 (s), 1437 (s), 1322 (s), 1257 (s), 1220 (m), 1129 (s), 1070 (m), 1051 (s), 1009 (s), 980 (s), 883 (m), 803 (m), 758 (m), 733 (m); ¹H NMR (200 MHz, CDCl₃): δ 7.63 (dd, $J_I = 6.4$ Hz, $J_2 = 2.0$ Hz, 2H), 7.37 (dd, $J_I = 6.6$ Hz, $J_2 = 2.0$ Hz, 2H), 6.70 (d, J = 4.4 Hz, 2H), 6.36 (d, J = 4.2 Hz, 2H), 3.07 (q, J = 7.6 Hz, 4H), 1.34 (t, J = 7.6, 6H); ¹³C NMR (50 MHz, CDCl₃): δ 164.3, 141.4, 134.2, 133.3, 132.0, 131.7, 130.4, 124.6, 117.8, 22.3, 12.9. HRMS FABS (M+H⁺) Calcd for C₁₉H₁₉BBrF₂N₂: 403.0793. Found: 403.0797.

BODIPY 27. According to GP1. **1b** (20.0 mg, 0.068 mmol), 3bromophenylboronic acid (50.0 mg, 0.204 mmol), Pd₂(dba)₃ (1.5 mg, 1.7x10⁻³ mmol), TFP (1.2 mg, 5.0x10⁻³ mmol), and CuTC (38.8 mg, 0.204 mmol). T he desired product (17.5 mg, 64%) was obtained as an orange solid. TLC (15% EtOAc/hexanes, $R_f = 0.62$); mp 124-126 °C; IR (KBr, cm⁻¹): 2968 (w), 2939 (w), 1574 (s), 1550 (s), 1488 (s), 1432 (s), 1342 (m), 1320 (s), 1280 (s), 1152 (s), 1139 (s), 1089 (m), 1058 (m), 1039 (s), 985 (s), 899 (m), 798 (m), 761 (m), 733 (m), 720 (m); ¹H NMR (200 MHz, CDCl₃): δ 7.69-7.650 (m, 2H), 7.46-7.27 (m, 2H), 6.73 (d, J = 4.4 Hz, 2H), 6.37 (d, J = 4.2 Hz, 2H), 3.09 (q, J = 7.5 Hz, 4H), 1.35 (t, J = 7.6, 6H); ¹³C NMR (50 MHz, CDCl₃): δ 164.4, 140.8, 136.3, 134.2, 133.1, 133.1, 130.4, 129.9, 129.1, 122.5, 117.9 22.3, 12.9. HRMS FABS (M+H⁺) Calcd for C₁₉H₁₉BBrF₂N₂: 403.0793. Found: 403.0798.

BODIPY 28. According to GP1. **1b** (17.8 mg, 0.066 mmol), *o*bromophenylboronic acid (39.7 mg, 0.198 mmol), Pd₂(dba)₃ (1.5 mg, 1.6x10⁻³ mmol), TFP (1.1 mg, 4.9x10⁻³ mmol), and CuTC (37.6 mg, 0.198 mmol). The product (20.0 mg, 82%) was obtained as red crystals. TLC (15 % EtOAc/hexanes, $R_f = 0.52$); mp 111-113 °C; IR (KBr, cm⁻¹): 3118 (w), 3063 (w), 2979 (w), 2961 (w), 2932 (w), 2872 (w), 1566 (s), 1555 (s), 1490 (m), 1462 (m), 1435 (m), 1345 (w), 1309 (m), 1284 (s), 1212 (w), 1140 (s), 1212 (w), 1140 (s), 1087 (m), 1025 (s), 1000 (s), 982 (s), 885 (w), 796 (m), 746 (m), 736 (m), 704 (w); ¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, *J* = 7.7 Hz, 1H), 7.45 – 7.31 (m, 3H), 6.52 (d, *J* = 4.2 Hz, 2H), 6.32 (d, *J* = 4.2 Hz, 2H), 3.08 (q, *J* = 7.6 Hz, 4H), 1.35 (t, *J* = 7.6 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 165.0, 140.8, 135.5, 134.8,

The Journal of Organic Chemistry

133.5, 132.0, 131.1, 130.2, 127.2, 123.5, 117.9, 117.8, 21.3, 12.3. HRMS FABS (M+H⁺) Calcd for C₁₉H₁₉BBrF₂N₂: 403.0793. Found: 403.0798.

BODIPY 29. According to GP1. **1a** (20.0 mg, 0.084 mmol), *p*-iodophenylboronic acid (62.5 mg, 0.252 mmol), Pd₂(dba)₃ (1.9 mg, 2.1 x10⁻³ mmol), TFP (1.6 mg, 6.3 x10⁻³ mmol), and CuTC (48 mg, 0.252 mmol). The desired product (27.1 mg, 83%) was obtained as an orange solid. TLC (30% EtOAc/hexanes, $R_f = 0.45$); mp 193-195 °C; IR (KBr, cm⁻¹): 3106 (w), 1563 (s), 1538 (s), 1478 (m), 1414 (s), 1395 (s), 1260 (s), 1224 (m), 1155 (m), 1116 (s), 1082 (s), 976 (m), 908 (m), 774 (m), 739 (m) ¹H NMR (200 MHz, CDCl₃): δ 7.95(s, 2H), 7.89(d, *J* = 8.4 Hz, 2H), 7.30 (d, *J* = 8.4 Hz, 2H), 6.91 (d, *J* = 3.6 Hz, 2H), 6.56 (d, *J* = 3.6 Hz, 2H); ¹³C NMR (50 MHz, CDCl₃): δ 144.7, 137.9, 134.7, 133.3, 132.0, 131.47, 119.0, 118.94, 97.64. HRMS FABS (M+H⁺) Calcd for C₁₅H₁₁BF₂IN₂: 395.0028. Found: 395.0021.

BODIPY 30. According to GP1. **1a** (50.0 mg, 0.210 mmol), 4-(trimethylsilyl)phenylboronic acid (122.0 mg, 0.630 mmol), Pd₂(dba)₃ (4.8 mg, 5.2x10⁻³ mmol), TFP (3.6 mg, 1.6x10⁻³ mmol), and CuTC (119.7 mg, 0.630 mmol). The desired product (52.4 mg, 73%) was obtained as an orange solid. TLC (30% EtOAc/hexanes, R_f = 0.83); mp 158-159 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.95 (s, 2H), 7.61 (dd, *J* = 49.5, 8.0 Hz, 4H), 6.97 (d, *J* = 4.1 Hz, 2H), 6.55 (d, *J* = 3.2 Hz, 2H), 0.34 (s, 9H).³⁹

BODIPY 31. According to GP1. **1a** (10.0 mg, 0.042 mmol), 4chlorophenylboronic acid (19.7 mg, 0.126 mmol), $Pd_2(dba)_3$ (1.0 mg, 1.0 x10⁻³ mmol), TFP (0.7 mg, 1.0 x10⁻³ mmol) and CuTC (23.9 mg, 0.126 mmol). The desired product (10.9 mg, 86%) was obtained as an orange-reddish solid. TLC (15% AcOEt/Hexanes R_f = 0.36); mp= 199-200 °C; IR (KBr, cm⁻¹): 3134 (w), 3107 (w), 1572 (s), 1543 (s), 1413 (s),

ACS Paragon Plus Environment

1401 (s), 1384 (s), 1260 (s), 1155 (m), 1116 (s), 1081 (s), 1049 (m), 979 (m).¹H NMR (200 MHz, CDCl₃) δ 7.96 (s, 2H), 7.51 (s, 4H), 6.92-6.90 (m, 2H), 6.57-6.55 (m, 2H); ¹³C NMR (50 MHz, CDCl₃) δ 145.9, 144.7, 137.5, 134.9, 132.4, 131.9, 131.5, 129.1, 119.0. HRMS FABS (M+H⁺) Calcd for C₁₅H₁₁BClF₂N₂: 303.0672. Found: 303.0674.

BODIPY 32. According to GP1. **1b** (40 mg, 0.136 mmol), 4carboxyphenylboronic acid (68.0 mg, 0.408 mmol), Pd₂(dba)₃ (3.0 mg, 3.4×10^{-3} mmol), TFP (3.0 mg, 0.011 mmol) and CuTC (78.0 mg, 0.411 mmol). The desired product (40 mg, 80%) was obtained as a red solid. TLC (15% EtOAc/hexanes, R_f = 0.33); mp 202-203 °C; IR (KBr, cm⁻¹): 2974 (m), 1710 (s), 1575 (s), 1555 (s), 1438 (s), 1275 (s), 1140 (s), 1034 (m), 886 (w), 801 (w), 723 (m), 541 (m); ¹H NMR (200 MHz, CDCl₃): δ 8.23 (d, *J*= 8.0 Hz, 2H), 7.62 (d, *J*= 8.0 Hz, 2H), 6.70 (d, *J*= 4.0 Hz, 2H), 3.07 (q, *J*= 7.0 Hz, 4H), 1.35 (t, *J*= 7.5 Hz, 6H); ¹³C NMR (50 MHz, (CD₃)₂CO/CD₃SO, 3:1): δ 164.2, 142.8, 138.3, 135.0, 134.3, 132.9, 132.6, 131.2, 129.2, 118.6, 22.6, 13.3. HRMS FABS (M+H⁺) Calcd for C₂₀H₂₀BF₂N₂O₂: 369.1586. Found: 369.1589.

BODIPY 33. According to GP1. **1a** (50.0 mg, 0.210 mmol), 3-(hydroxymethyl)phenylboronic acid (95.7 mg, 0.630 mmol), Pd₂(dba)₃ (5.0 mg, 5.3 x10⁻³ mmol), TFP (3.7 mg, 1.6 x10⁻³ mmol) and CuTC (119.7 mg, 0.630 mmol). The desired product (60.1 mg, 96%) was obtained as a red solid. TLC (30% EtOAc/hexanes, $R_f = 0.17$); mp 121-123 °C; IR (KBr, cm⁻¹): 3400 (s), 2892 (m), 1545 (s), 1476 (m), 1414 (s), 1389 (s), 1260 (s), 1190 (m), 1116 (s), 1081 (s), 991 (m), 775 (m), 736 (m), 607 (w), 583 (w); ¹H NMR (500 MHz, CDCl₃) δ 7.95 (s, 2H), 7.55 (ddd, J = 21.0, 14.1, 7.5 Hz, 4H), 6.93 (d, J = 3.7 Hz, 2H), 6.55 (d, J = 3.0 Hz, 2H), 4.82 (s, 2H). ¹³C NMR (75 MHz,

The Journal of Organic Chemistry

CDCl₃): δ 147.5, 144.5, 141.7, 134.3, 131.9, 129.9, 129.4, 129.0, 128.9, 118.8, 64.9. HRMS FABS (M+H⁺) Calcd for C₁₆H₁₄BF₂N₂O: 299.1167. Found: 299.1160.

BODIPY 34. According to GP1. **1b** (25.0 mg, 0.085 mmol) and 2biphenylboronic acid (50.0 mg, 0.255 mmol), Pd₂(dba)₃ (1.0 mg, 2.1x10⁻³ mmol), TFP (1.0 mg, $6.3x10^{-3}$ mmol) and CuTC (48.0 mg, 0.2550 mmol). The desired product (32.0 mg, 90%) was obtained as orange crystals. TLC (15% EtOAc/hexanes, R_f = 0.48); mp 145-147 °C; IR (KBr, cm⁻¹): 2929 (w), 1566 (s), 1554 (s), 1488 (w), 1434 (w), 1314 (m), 1287 (m), 1140 (s), 1127 (s), 1021 (s), 1002 (s), 982 (m), 746 (m), 720 (w),700 (w); ¹H RMN (200 MHz, CDCl₃): δ 7.55-7.54 (m, 2H), 7.44-7.42 (m, 2H), 7.26-7.19 (m, 5H), 6.54 (d, *J*= 4.0 Hz, 2H), 6.19 (d, *J*= 4.4 Hz, 2H), 3.03-2.97 (m, 4H), 1.28 (t, *J*= 7.4 Hz, 6H); ¹³C RMN (50 MHz, CDCl₃): δ 163.2, 142.3, 141.9, 140.4, 134.9, 132.6, 131.5, 130.5, 130.2, 129.7, 128.6, 128.4, 127.3, 126.7, 117.1, 22.0, 12.6. HRMS FABS (M+H⁺) Calcd for C₂₅H₂₄BF₂N₂: 401.2001. Found: 401.2005.

BODIPY 35. According to GP1. **1b** (10.0 mg, 0.034 mmol), 6-methoxy-2naphthaleneboronic acid (20.6 mg, 0.102 mmol), Pd₂(dba)₃ (0.8 mg, 8.5x10⁻⁴ mmol), TFP (0.6 mg, 2.5x10⁻³ mmol), and CuTC (19.4 mg, 0.102 mmol). The desired product (10.8 mg, 79%) was obtained as an orange solid. TLC (20% EtOAc/hexanes, $R_f = 0.54$); mp 185-187 °C; IR (KBr, cm⁻¹): 2973 (w), 1626 (m), 1556 (s), 1491 (s), 1438 (s), 1390 (m), 1319 (s), 1272 (s), 1203 (s), 1147 (s), 1075 (m), 1031(s), 1009 (s), 987 (s); ¹H NMR (200 MHz, CDCl₃): δ 7.92 (s, 1H), 7.81 (dd, J_I = 7.8 Hz, J_2 = 2.6 Hz, 2H), 7.57 (dd, J_I = 8.4 Hz, J_2 = 1.6 Hz, 1H), 7.21 (s, 2H), 6.79 (d, J= 4.0 Hz, 2H), 6.36 (d, J= 4.2 Hz, 2H), 3.97 (s, 3H), 3.09 (q, J= 7.8 Hz, 4H), 1.35 (t, J= 7.6 Hz, 6H); ¹³C NMR (50 MHz, CDCl₃): δ 163.5, 159.1, 143.4, 135.5, 134.7, 130.8, 130.4, 130.3, 129.8, 128.5, 128.3, 126.8, 120.1, 117.4, 105.9, 55.7, 22.3, 13.0. HRMS FABS (M+H⁺) Calcd for $C_{24}H_{24}BF_2N_2O$: 405.1950. Found: 405.1954.

BODIPY 36. According to GP1. **1a** (100.0 mg, 0.420 mmol), *p*-tolylboronic acid (171.3 mg, 1.260 mmol), $Pd_2(dba)_3$ (9.6 mg, 0.011 mmol), TFP (7.3 mg, 0.032 mmol) and CuTC (240.3 mg, 1.260 mmol). The desired product (111.1 mg, 93%) was obtained as orange crystals. ¹H NMR (200 MHz, CDCl₃) δ 7.93 (s, 2H), 7.48 (d, *J* = 8 Hz, 2H), 7.33 (d, *J* = 8 Hz, 2H), 6.95 (d, *J* = 4.2 Hz, 2H), 6.54 (d, *J* = 3.2 Hz, 2H), 2.48 (s, 3H).⁴⁰

BODIPY 37. According to GP1. **1b** (20.0 mg, 0.068 mmol) and 1-(phenylsulfonyl)-2-indolylboronic acid (61.4 mg, 0.204 mmol), Pd₂(dba)₃ (1.5 mg, $1.7x10^{-3}$ mmol), TFP (1.2 mg, 5.0x10⁻³ mmol), and CuTC (38.8 mg, 0.204 mmol). The desired product (20.5 mg, 60%) was obtained as an orange solid. TLC (15% AcOEt/hexanes R_f = 0.25); mp 176-178 °C; IR (KBr, cm⁻¹): 3158 (w), 3119 (w), 2974 (w), 2937 (w), 2880 (w), 1580 (s), 1559 (s), 1489 (s), 1437 (s), 1376 (s), 1322 (s), 1275 (m), 1187 (m), 1174 (m), 1140 (s), 1089 (m), 1039 (s), 1011 (m), 972 (m), 962 (m), 851 (m), 797 (m), 763 (m), 730 (s), 686 (m), 592 (s), 571 (s), 553 (m).¹H NMR (200 MHz, CDCl₃) δ 8.10-7.95 (m, 3H), 7.84 (s, 1H), 7.63-7.27 (m, 6H), 6.80 (d, *J*= 4.2 Hz, 2H), 6.32 (d, *J*= 4.2 Hz, 2H), 3.09 (q, *J*= 7.8 Hz, 4H), 1.35 (t, *J*= 7.4, 6H); ¹³C NMR (50 MHz, CDCl₃) δ 164.2, 138.0, 135.1, 134.6, 134.2, 133.5, 130.6, 129.9, 129.8, 127.9, 127.1, 126.0, 124.3, 121.3, 117.4, 117.1, 113.9, 22.3, 13.0. HRMS FABS (M+H⁺) Calcd for C_{27H25}BF₂N₃O₂S: 504.1729. Found: 504.1732.

BODIPY 38. According to GP1. **1a** (50.0 mg, 0.210 mmol) and 2-fluoro-5iodophenylboronic acid (167.5 mg, 0.630 mmol), $Pd_2(dba)_3$ (4.8 mg, 5.2x10⁻³ mmol),

TFP (3.6 mg, 1.6 x10⁻³ mmol), and CuTC (119.7 mg, 0.630 mmol). The desired product (53.5 mg, 62%) was obtained as a red solid. TLC (20% EtOAc/hexanes, $R_f = 0.46$); mp 143-145 °C; IR (KBr, cm⁻¹): 3130 (w), 3101 (w), 1569 (s), 1547 (s), 1412 (s), 1387 (s), 1259 (s), 1106 (s),1071 (s), 1040 (s), 986 (s); ¹H NMR (200 MHz, CDCl₃): δ 7.94 (s, 2H), 7.88-7.74 (m, 2H), 7.03 (t, J = 9.2 Hz, 1H), 6.84 (d, J = 4.0 Hz, 2H), 6.54 (d, J = 4.2 Hz, 2H); ¹³C NMR (50 MHz, CDCl₃): δ 159.7 (d, J = 251.5 Hz), 145.6, 141.3 (d, J = 7.6 Hz), 140.3, 138.4, 135.1, 131.3, 123.9 (d, J = 15.9 Hz), 119.3, 118.7 (d, J = 22.7 Hz), 86.9 (d, J = 3.8 Hz). HRMS FABS (M+H⁺) Calcd for C₁₅H₁₀BF₃IN₂: 412.9934. Found: 412.9933.

BODIPY 39. According to GP1. **1b** (25.0 mg, 0.085 mmol) and 1-*N*-Bocpyrrole-2-boronic acid (53.0 mg, 0.255 mmol), Pd₂(dba)₃ (1.0 mg, 2.1x10⁻³ mmol), TFP (1.0 mg, $6.3x10^{-3}$ mmol), and CuTC (48.0 mg, 0.255 mmol). The desired product (25 mg, 66%) was obtained as red crystals. TLC (15% EtOAc/hexanes, R_f = 0.56); mp 130-132 °C; IR (KBr, cm⁻¹): 2972 (w), 2932 (w), 1753 (s), 1561 (s), 1488 (m), 1436 (m), 1308 (s), 1260 (s), 1129 (s), 1054 (s), 1015 (s), 979 (s), 825 (w), 805 (w), 761 (m), 729 (m); ⁻¹H RMN (200 MHz, CDCl₃): δ 7.54-7.51 (m, 1H), 6.78 (d, *J*= 4.4 Hz, 2H), 6.51-6.48 (m, 1H), 6.36-6.33 (m, 3H), 3.06 (q, *J* = 7.4 Hz, 4H), 1.34 (t, *J*= 7.6 Hz, 6H), 1.23 (s, 9H); ¹³C RMN (50 MHz, CDCl₃): δ 163.1, 148.7, 134.7, 129.2, 125.7, 124.9, 119.5, 117.1, 111.1, 85.1, 27.3, 22.1, 13.0. HRMS FABS (M+H⁺) Calcd for C₂₂H₂₇BF₂N₃O₂: 414.2164. Found: 414.2169.

BODIPY 40. According to GP1. **1b** (50.0 mg, 0.170 mmol) and 4formylphenylboronic acid (76.0 mg, 0.510 mmol), $Pd_2(dba)_3$ (3.8 mg, $4.2x10^{-3}$ mmol), TFP (2.9 mg, 0.013 mmol), and CuTC (96.9 mg, 0.510 mmol). The desired product (52.9 mg, 88%) was obtained as an orange solid. TLC (30% EtOAc/hexanes, $R_f = 0.60$); mp 159-160 °C; IR (KBr, cm⁻¹): 3437 (w), 2970 (w), 2925 (w), 1699 (m), 1605 (w), 1572 (s), 1550 (s), 1493 (m), 1436 (m), 1342 (s), 1321 (m), 1275 (m), 1137 (s) 1035 (m), 1008 (m), 978 (m), 804 (w); ¹H NMR (400 MHz, CDCl₃) δ 10.12 (s, 1H), 8.00 (d, *J* = 8.4 Hz, 2H), 7.66 (d, *J* = 8.4 Hz, 2H), 6.67 (d, *J* = 5.1 Hz, 2H), 6.37 (d, *J* = 4.9 Hz, 2H), 3.08 (dd, *J* = 16.0, 8.1 Hz, 4H), 1.34 (t, *J* = 7.8 Hz, 6H). HRMS FABS (M+H⁺) Calcd for C₂₀H₂₀BF₂N₂O: 353.1637. Found: 353.1631.

BODIPY 42. According to GP1. **1b** (30.0 mg, 0.102 mmol), 4-(trimethylsilyl)phenylboronic acid (59.0 mg, 0.306 mmol), Pd₂(dba)₃ (2.4 mg, 2.6x10⁻³ mmol), TFP (1.8 mg, 7.6x10⁻³ mmol), and CuTC (58.3 mg, 0.306 mmol). The desired product (39.4 mg, 97%) was obtained as orange crystals. TLC (10% EtOAc/Hexanes, R_f = 0.80); mp 160-162 C; IR (KBr, cm⁻¹): 2966 (w), 1562 (s), 1488 (m), 1402 (w), 1324 (s), 1261 (m), 1131 (s), 1045 (s), 1009 (m), 982 (m), 850 (m); ¹H NMR (200 MHz, CDCl₃): δ 7.62 (d, *J*= 8.0 Hz, 2H), 7.46 (d, *J*= 8.0 Hz, 2H), 6.77 (d, *J*= 4.0 Hz, 2H), 6.34 (d, *J*= 4.4 Hz, 2H), 3.09 (q, *J*= 7.5 Hz, 4H), 1.35 (t, *J*= 7.5 Hz, 6H), 0.33 (s, 9H); ¹³C NMR (50 MHz, CDCl₃): δ 163.7, 143.4, 143.2, 134.8, 134.5, 133.3, 130.8, 129.9, 117.4, 22.3, 13.1, 0.0. HRMS FABS (M+H⁺) Calcd for C₂₂H₂₈BF₂N₂Si: 397.2083. Found: 397.2085.

BODIPY 43. According to GP1. **1a** (50.0 mg, 0.210 mmol), 2methoxycarbonylphenylboronic acid (113.4 mg, 0.630 mmol), Pd₂(dba)₃ (4.8 mg, 5.2 x10⁻³ mmol), TFP (3.6 mg, 1.6x10⁻³ mmol), and CuTC (119.7 mg, 0.630 mmol). The desired product (44.0 mg, 65%) was obtained as orange crystals. TLC (15% EtOAc/hexanes, R_f = 0.18); mp 135-137 °C; IR (KBr, cm⁻¹): 3117 (w), 1732 (s), 1541 (s),

 1388 (s), 1258 (s), 1112 (s), 1075 (vs), 913 (w), 774 (w), 728 (m); ¹H RMN (200 MHz, CDCl₃): δ 8.12-8.08 (m, 1H), 7.93 (s, 2H), 7.68-7.63 (m, 2H), 7.50-7.46 (m, 1H), 6.70-6.68 (m, 2H), 6.50-6.48 (m, 2H), 3.59 (s, 3H); ¹³C RMN (50 MHz, CDCl₃): δ 166.6, 147.2, 144.1, 135.3, 133.864, 131.9, 131.6, 130.9, 130.7, 130.1, 118.5, 52.4. HRMS FABS (M+H⁺) Calcd for C₁₇H₁₄BF₂N₂O₂: 327.1116. Found: 327.1119.

BODIPY 44. According to GP1. **1a** (100.0 mg, 0.420 mmol), 5-formyl-2methoxyphenylboronic acid (227.0 mg, 1.260 mmol), Pd₂(dba)₃ (9.6 mg, 0.012 mmol), TFP (7.3 mg, 0.031 mmol), CuTC (339.5 mg, 1.260 mmol). The desired product (128.0 mg, 93%) was obtained as a dark red solid. TLC (30% EtOAc/Hexanes $R_f = 0.3$); mp 121-122 °C; IR (KBr, cm⁻¹): 3111 (w), 2930 (w), 2843 (w), 1694 (s), 1599 (s), 1559 (s), 1495 (m), 1412 (s), 1388 (s), 1356 (m), 1261 (s), 1224 (w), 1192 (m), 1179 (m), 1156 (w), 1111 (s), 1075 (s), 1047 (m), 998 (w), 955 (w), 839 (w), 822 (w), 784 (m), 764 (m), 745 (w), 717 (w), 609 (w), 555 (m), 414 (m); ¹H (300 MHz, CDCl₃) δ 9.95 (s, 2H), 8.07 (d, *J*= 8.4 Hz, 1H), 7.93 (s, 2H), 7.86 (s, 1H), 7.18 (d, *J* = 8.4 Hz, 1H), 6.75 (s, 2H), 6.51 (s, 2H), 3.86 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 190.0, 162.1, 144.7, 142.2, 135.6, 133.7, 133.1, 130.9, 129.4, 123.3, 118.7, 111.7, 56.3. HRMS FABS (M+H⁺) Calcd for C₁₇H₁₄BF₂N₂O₂: 327.1116. Found: 327.1120.

BODIPY 45. According to GP1. **1a** (50.0 mg, 0.210 mmol), 2-(hydroxymethyl)phenylboronic acid (95.7 mg, 0.630 mmol), Pd₂(dba)₃ (5.0 mg, 5.3x10⁻³ mmol), TFP (3.7 mg, 1.6x10⁻³ mmol), and CuTC (119.7 mg, 0.630 mmol). The desired product (60.1 mg, 94%) was obtained as a bright red solid. TLC (40% Acetone/Hexanes R_f = 0.4); mp 149-150 °C.¹H (300 MHz, CDCl₃) δ 7.93 (s, 2H), 7.67 (d, *J*= 7.5 Hz, 1H), 7.56 (t, *J*= 7.5 Hz, 1H), 7.41 (t, *J*= 7.5 Hz, 1H), 7.31 (d, *J*= 7.5 Hz, 1H), 6.71 (s, 2H), 6.50 (s, 2H), 4.58 (s, 2H), 1.75 (s, 1H).⁴¹

BODIPY 46. According to GP1. **1a** (25.0 mg, 0.105 mmol) and benzo[b]thien-2ylboronic acid (56.0 mg, 0.315 mmol), Pd₂(dba)₃ (2.4 mg, 0.003 mmol), TFP (1.8 mg, 0.008 mmol), and CuTC (60.0 mg, 0.315 mmol). The desired product (28.8 mg, 85%) was obtained as red crystals. TLC (15 % EtOAc/Hexanes $R_f = 0.32$); mp 213-215 °C; IR (KBr, cm⁻¹): 3122 (w), 3064 (w), 1541 (s), 1476 (m), 1411 (s), 1386 (s), 1353 (m), 1261 (s), 1208 (w), 1183 (w), 1158 (w), 1113 (s), 1079 (s), 1040 (s), 966 (m), 935 (w), 892 (w), 872 (w), 808 (w), 769 (m), 744 (m), 731 (w), 628 (w), 597 (w), 549 (w); ¹H NMR (400 MHz, CDCl₃) δ 7.99 – 7.87 (m, 4H), 7.76 (s, 1H), 7.52 – 7.43 (m, 2H), 7.32 (d, J =4.1 Hz, 2H), 6.58 (d, J = 3.7 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 144.93, 142.13, 140.19, 139.55, 135.07, 134.76, 132.38, 130.30, 126.95, 125.83, 125.31, 122.58, 119.20. HRMS FABS (M+H⁺) Calcd for C₁₇H₁₂BF₂N₂S: 325.0782. Found: 325.0786.

General procedure for the L-S cross-coupling with boronic acids under microwave irradiation (GP2). A thick-walled tube equipped with a stir bar was charged with 1a (1 equiv), the corresponding boronic acid (3 equiv), and dry THF (3 mL). The mixture was sparged with N₂ for 5 min whereupon $Pd_2(dba)_3$ (2.5 mol%), trifurylphosphine (7.5%), and CuTC (3 equiv) were added under N₂. The tube was sealed and heated under microwave irradiation at 100 °C (200 psi, 150 W) for the corresponding reaction time (see Table 1). After the reaction mixture reached rt, the crude material was adsorbed in SiO₂-gel and the product was purified by flash chromatography on SiO₂-gel using EtOAc/hexanes gradients. For purposes of characterization, the products were crystallized from CH₂Cl₂/petroleum ether.

The Journal of Organic Chemistry

BODIPY 33. According to GP2. **1a** (50.0 mg, 0.210 mmol), 3- (hydroxymethyl)phenylboronic acid (95.7 mg, 0.630 mmol), $Pd_2(dba)_3$ (5.0 mg, 5.3 x10⁻³ mmol), TFP (3.7 mg, 1.6 x10⁻³ mmol) and CuTC (119.7 mg, 0.630 mmol). The desired product (59.4 mg, 95%) was obtained as a red solid. Characterization data is given above.

BODIPY 12. According to GP2. **1a** (25 mg, 0.105 mmol), 2bromophenylboronic acid (63 mg, 0.315 mmol), Pd₂(dba)₃ (2.4 mg, 0.003 mmol), TFP (1.8 mg, 0.008 mmol) and CuTC (60 mg, 0.315 mmol). The desired product (31 mg, 85%) was obtained as orange crystals; mp 150-152 °C; ¹H NMR (200 MHz, CDCl₃) δ 7.95 (s, 2H), 7.76-7.71 (m, 1H), 7.47-7.37 (m, 3H), 6.72 (d, *J*= 4.0, 2H), 6.51 (d, *J*= 4.4, 2H).¹⁹

BODIPY 31. According to GP2. **1a** (25 mg, 0.105 mmol), 4-clorophenylboronic acid (49 mg, 0.315 mmol), $Pd_2(dba)_3$ (2.4 mg, 0.003 mmol), TFP (1.8 mg, 0.008 mmol) and CuTC (60 mg, 0.315 mmol). The desired product (28 mg, 90%) was obtained an orange-reddish solid. Characterization data given above.

BODIPY 4. According to GP2. **1a** (25 mg, 0.105 mmol), 4-biphenylboronic acid (62 mg, 0.315 mmol), Pd₂(dba)₃ (2.4 mg, 0.003 mmol), TFP (1.8 mg, 0.008 mmol) and CuTC (60 mg, 0.315 mmol). The desired product (33 mg, 92%) was obtained as orange-red crystals; mp 212-213 °C. ¹H NMR (200 MHz, CDCl₃) δ 7.96 (s, 2H), 7.78-7.639 (m, 6H), 7.55-7.425 (m, 3H), 7.03 (d, *J*= 4 Hz, 2H), 6.57 (d, *J*= 2.8 Hz, 2H).¹⁹

BODIPY 8. According to GP2. **1a** (25 mg, 0.105 mmol), 4methoxyphenylboronic acid (48 mg, 0.315 mmol), $Pd_2(dba)_3$ (2.4 mg, 0.003 mmol), TFP (1.8 mg, 0.008 mmol) and CuTC (60 mg, 0.315 mmol). The desired product (28 mg, 91%) was obtained as orange crystals; mp 137-138 °C. ¹H NMR (200 MHz, CDCl₃) δ 7.92 (s, 2H), 7.55 (dt, J_1 = 8.8 Hz, J_2 = 2.1 Hz, 2H), 7.05 (dt, J_1 = 9.0 Hz, J_2 = 2.2 Hz, 2H), 6.98 (d, J= 4.0 Hz, 2H), 6.56-6.54 (m, 2H), 3.92 (s, 3H).¹⁹

General procedure for the L-S cross-coupling with organostannanes using Cu(I) Phosphinate as Cu(I) Source (GP3). A Schlenk tube was charged under N₂ with dry THF (2 mL), methylthiobodipy **1a** (1 equiv.), the organostannane (3 equiv.), Pd(PPh₃)₄ (5%) and Cu(I) phosphinate (3 equiv). Then the reaction flask was immersed into a preheated oil-bath at 55 °C. The reaction progress was followed by TLC (SiO₂-gel, 20% EtOAc/hexanes). After the starting material was consumed, the mixture was allowed to cool to r.t. and the solvent was removed in vacuo. The product was obtained after flash-chromatography (SiO₂-gel, EtOAc/hexanes gradient) followed by crystallization in petroleum ether.

BODIPY 8. According to GP3. **1a** (25 mg, 0.105 mmol), 4methoxyphenyltributylstannane (125 mg, 0.315 mmol), Pd(PPh₃)₄ (6.0 mg, 5 mol%), and CuOP(O)Ph₂ (88 mg, 0.315 mmol). The desired product (26 mg, 85%) was obtained as orange crystals; mp 137-138 °C. ¹H NMR (200 MHz, CDCl₃) δ 7.92 (s, 2H), 7.55 (dt, J_I = 8.8 Hz, J_2 = 2.1 Hz, 2H), 7.05 (dt, J_I = 9.0 Hz, J_2 = 2.2 Hz, 2H), 6.98 (d, J= 4.0 Hz, 2H), 6.56-6.54 (m, 2H), 3.92 (s, 3H).¹⁹

BODIPY 36. According to GP3. **1a** (25 mg, 0.105 mmol), 4methylphenyltributylstannane (120 mg, 0.315 mmol), Pd(PPh₃)₄ (6.0 mg, 5 mol%), and CuOP(O)Ph₂ (88 mg, 0.315 mmol). The desired product (23 mg, 77%) was obtained as orange crystals. ¹H NMR (200 MHz, CDCl₃) δ 7.93 (s, 2H), 7.48 (d, *J* = 8 Hz, 2H), 7.33 (d, *J* = 8 Hz, 2H), 6.95 (d, *J* = 4.2 Hz, 2H), 6.54 (d, *J* = 3.2 Hz, 2H), 2.48 (s, 3H). ⁴⁰

BODIPY 31. According to GP3. **1a** (25 mg, 0.105 mmol), 4chlorophenyltributylstannane (126 mg, 0.315 mmol), $Pd(PPh_3)_4$ (6.0 mg, 5 mol%), and $CuOP(O)Ph_2$ (88 mg, 0.315 mmol). The desired product (26 mg, 81%) was obtained as orange-reddish solid. Characterization data are given above.

BODIPY 48. According to GP3. **1a** (25 mg, 0.105 mmol), 3-(1,3-benzodioxole)tributylstannane (129 mg, 0.315 mmol), Pd(PPh₃)₄ (6.0 mg, 5 mol%), and CuOP(O)Ph₂ (88 mg, 0.315 mmol). The desired product (25 mg, 75%) was obtained as red solid; TLC (25 % EtOAc/Hexanes $R_f = 0.31$); mp 133-134 °C. IR 3117 (m), 2901 (bs), 1551 (bs), 1412 (s), 1388 (s), 1263 (s), 1254 (s), 1117 (s), 1079 (s), 1044 (s); ¹H NMR (CDCl₃): $\delta = 6.11$ (2, s), 6.55 (2, bd, J = 3.2), 6.94-7.02 (3, m), 7.08-7.14 (2, m), 7.92 (2, bs); ¹³C NMR (CDCl₃): $\delta = 102.1$, 108.7, 111.1, 118.6, 125.8, 127.9, 131.5, 135.1, 144.0, 147.2, 148.2, 150.5. HRMS FABS (M+H⁺) Calcd for C₁₆H₁₂BF₂N₂O₂: 313.0960. Found: 313.0959.

BODIPY 2. According to GP3. **1a** (25 mg, 0.105 mmol), phenyltributylstannane (115 mg, 0.315 mmol), Pd(PPh₃)₄ (6.0 mg, 5 mol%), and CuOP(O)Ph₂ (88 mg, 0.315 mmol). The desired product (25 mg, 90%) was obtained as orange crystals. ¹H NMR (200 MHz, CDCl₃): δ 7.95 (s, 2H), 7.61-7.53 (m, 5 H), 6.94 (d, J= 4.4 Hz, 2.0 H), 6.55 (d, *J* = 3.8 Hz, 2H).²²

Acknowledgments

We thank CONACyT (Grants 129572 and 123732), DAIP-UG 2014, MINECO

(MAT2014-51937-C3-3) and Gobierno Vasco (IT339-10) for financial support. B. Z. T.

wishes to thank Hong Kong Research Grants Council (Project No. 603008). We also

thank Cuantico de Mexico (<u>www.cuantico.mx</u>) for the kind donation of BODIPYs 1a,b.

Supporting Information Available: Copies of the ¹H and ¹³C NMR spectra of all the compounds described, full photophysical data. This material is available free of charge via the Internet at http://pubs.acs.org.

REFERNCES

- (1) (a) Molecular Probes Inc., Eugene, Oregon, USA. (b) R. P. Haugland, *The Handbook. A Guide to Fluorescent Probes and Labeling Technologies*, 10th edn. Molecular Probes Inc., Eugene, Oregon, USA.
- (2) Treibs, A.; Kreuzer, F.-H. Liebigs. Ann. Chem. 1968, 718, 208.
- (3) (a) Ziessel; R.; Ulrich; G.; Harriman, A. New J. Chem. 2007, 31, 496. (b) Ulrich;
 G.; Ziessel, R.; Harriman, A. Angew. Chem, Int. Ed. 2008, 47, 1184. (c) Benniston, A. C.; Copley, G. Phys. Chem. Chem. Phys. 2009, 11, 4124. (d) Loudet; A.; Burgess, K.; Chem. Rev. 2007, 107, 4891. (e) Wood, T. E.; Thompson, A. Chem Rev. 2007, 107, 1831.
- (4) (a) West, R.; Panagabko, C.; Atkinson, J. J. Org. Chem. 2010, 75, 2883. (b) Ehrenschwender, T.; Wagenknecht, H.-A. Synthesis 2008, 3657.
- (5) (a) Rio,Y.; Seitz,W.; Gouloumis,A.; Vazquez, P.; Sessler, J. L.; Guldi, D. M.; Torres, T. *Chem. Eur. J.* 2010, *16*, 1929. (b) Koepf, M.; Trabolsi, A.; Elhabiri, M; Wytko, J. A.; Paul, D.; Albrecht-Gary, A. M.; Weiss, J. *Org. Lett.* 2005, *7*, 1279.
- (6) Lee, C. Y.; Hupp, J. T. Langmuir 2010, 26, 3760.
- (7) (a) Rao, M. R.; Mobin, S. M.; Ravikanth, M. *Tetrahedron* 2010, 66, 1728. (b) Vendrell, M.; Krishna, G. G.; Ghosh, K. K.; Zhai, D.; Lee, J-S; Zhu, Q.; Yau, Y. H.; Geifman Shochat, S.; Kim, H.; Chunge, J.; Chang, Y-T. *Chem. Commun.* 2011, 47, 8424. (c) Boens, N.; Qin, W.; Baruah, M.; De Borggraeve, W. M.; Filarowski, A.; Smisdom, N.; Ameloot, M.; Crovetto, L.;Talavera, E. M.; Alvarez-Pez, J. M. *Chem. Eur. J.* 2011, 17, 10924. (d) Boens, N.; Leen, V.; Dehaen, W. *Chem. Soc. Rev.* 2012, 41, 1130. (e) Cheng, T.; Wang, T.; Zhu, W.; Yang, Y.; Zeng, B.; Xu, Y. *Chem. Commun.* 2011, 47, 3915.
- (8) Godoy, J.; Vives, G.; Tour, J. M. Org. Lett. 2010, 12, 1464.
- (9) Lu, J.; Fu, H.; Zhang, Y.; Jakubek, Z. J.; Tao, Y.; Wang, S. Angew. Chem. Int. Ed. 2011, 50, 11658.
- (10) Baker, J. G.; Adams, L. A.; Salchow, K.; Mistry, S. N.; Middleton, R. J.; Hill, S. J.; Kellam, B. J. Med. Chem. 2011, 54, 6874.

1	
2	
ર	
4	
4	
5	
6	
7	
1	
8	
9	
1	Λ
4	4
1	1
1	2
1	3
1	1
4	4
1	5
1	6
1	7
4	Ω
ļ	0
1	9
2	0
2	1
~	2
2	2
2	3
2	4
2	5
~	5
2	6
2	7
2	8
2	0
2	9
3	0
3	1
ર	2
2	2
3	3
3	4
3	5
3	6
0	2
3	1
3	8
3	9
⊿	ñ
4	4
4	1
4	2
4	3
	1
4	4
4	5
4	6
Δ	7
-	0
4	Ø
4	9
5	0
5	1
5	ว
D	2
5	3
5	4
5	5
-	6
5	0
5	7
5	8
5	q

(11) Bura, T.; Leclerc, N.; Fall, S.; Léveque, P.; Heiser, T.; Ziessel, R. Org. Lett. **2011**, *13*, 6030.

- (12) Kim, D-R.; Ahn, H-C; Lee, W-J.; Ahn, D-R. Chem. Cummun. 2011, 47, 791.
- (13) Kang, N.-Y.; Lee, S.-C.; Park, S.-J.; Ha, H.-H.; Yun, S.-W.; Kostromina, E.; Gustavsson, N.; Ali, Y.; Chandran, Y.; Chun, H.-S.; Bae, M.; Ahn, J. H.; Han, W.; Radda, G. K.; Chang, Y.-T. *Angew. Chem. Int. Ed.* **2013**, *52*, 8557.
- (14) Xu, W.; Bai, J.; Peng, J.; Samanta, A.; Divyanshu, Chang, Y.-T. Chem. Commun. 2014, 50, 10398.
- (15) (a) Chen, J.; Burghart, A.; Derecskei-Kovacs, A.; Burgess, K. J. Org. Chem. 2000, 65, 2900. (b) Thorensen, L. H.; Kim, H.; Welch, M. B.; Burghart, A.; Burgess, K. Synlett 1998, 1276. (c) Goze, C.; Ulrich, G.; Ziessel, R. Org. Lett. 2006, 8, 4445. (d) Gose, C.; Ulrich, G.; Mallon, L. J.; Allen, B. D.; Harriman, A.; Ziessel, R. J. Am. Chem. Soc. 2006, 128, 10231 (e) Goze, C.; Ulrich, G.; Ziessel, R. J. Org. Chem. 2007, 72, 313. (f) Rohland, T.; Baruah, M.; Qin, W.; Boens, N.; Dehaen, W. Chem Comm. 2006, 266. (g) Rohland, T.; Qin, W.; Boens, N.; Dehaen, W. Eur. J. Org. Chem. 2006, 4658. (h) Tahtaoui, C.; Thomas, C.; Rohmer, F.; Klotz, P.; Duportail, G.; Mely, Y.; Bonnet, D.; Hibert, M. J. Org. Chem. 2007, 72, 269. (i) Dost, Z.; Atilgan, S.; Akkaya, E. U. Tetrahedron 2006, 62, 8484. (j) Yu, Y.-H.; Descalzo, A. B.; Shen, Z.; Röhr, H.; Liu, Q.; Wang, Y.-W.; Spieles, M.; Li, Y.-Z.; Rurack, K.; You, X.-Z. Chem. Asian J. 2006, 1-2, 176. (k) Lee, J-S.; Kang, N-y.; Kim, Y. K.; Samanta, A.; Feng, S.; Kim, H. K.; Vendrell, M.; Park, J. H.; Chang, Y-T J. Am. Chem. Soc. **2009**, 131, 10077. (1) Hayashi,Y.; Yamaguchi, S.; Cha, W. Y.; Kim, D.; Shinokubo, H. Org. Lett. 2011, 13, 2992. (m) Komatsu, T.; Urano, Y.; Fujikawa, Y.; Kobayashi, T.; Kojima, H.; Terai, T.; Hanaokaa, K.; Nagano, T. Chem. Commun. 2009, 7015. (n) Zheng, Q.; He, G. S.; Prasad, P. N. Chem. Phys. Lett. **2009**, 475, 250. (o) Bozdemir, Ö. A.; Büyükcakir, O.; Akkaya, E. U. Chem. *Eur. J.* **2009**, *15*, 3830. (p) Ikeda, C.; Ueda, S.; Nabeshima, T. Chem. Commun. **2009**, 2544. (q) Li, X.; Huang, S.; Hu, Y. Org. Biomol. Chem. **2012**, 10, 2369. (r) Khan, T. K.; Pissurlenkar, R. R. S.; Shaikh, M. S.; Ravikanth, M. J. Organomet. Chem. 2012, 697, 65. (s) Leen, V.; Leemans, T.; Boens, N.; Dehaen, W. Eur. J. Org. Chem. 2011, 4386. (t) Jiang, X-D.; Zhang, J.; Furuyama, T.; Zhao, W. Org. Lett. 2012, 14, 248. (u) Wu, W.; Guo, H.; Wu, W.; Ji, S.; Zhao, J. J. Org. Chem. 2011, 76, 7056. (v) Verbelen, B.; Leen, V.; Wang, L.; Boens, N.; Dehaen, W. Chem. Commun. 2012, 48, 9129. (w) Yokoi, H.; Wachi, N.; Hiroto, S.; Shinokubo, H. Chem. Commun. 2014, 50, 2715.
- (16) Ueno, T.; Urano, Y.; Kojima, H.; Nagano, T. J. Am. Chem. Soc. 2006, 128, 10640.
- (17) Bañuelos, J.; Arroyo-Córdoba, I. J.; Valois-Escamilla, I.; Alvarez-Hernández, A.; Peña-Cabrera, E.; Hu, R.; Tang, B. Z.; Esnal, I.; Martínez, V.; López Arbeloa, I. *RSC Advances* 2011, 1, 677.
 - (18) (a) Pochorovski, I.; Breiten, B.; Schweizer, W. B.; Diederich, F. Chem. Eur. J. 2010, 16, 12590. (b) Alamiry, M. A. H.; Benniston, A. C.; Copley, G.; Harriman, A.; Howgego, D. J. Phys. Chem. A. 2011, 115, 12111. (c) Röhr, H.; Trieflinger, C.; Rurack, K.; Daub, J. Chem. Eur. J. 2006, 12, 689. (d) Yu, H.; Xiao, Y.; Guo, H.; Qian, X. Chem. Eur. J. 2011, 17, 3179. (e) Wüstnera, D.;

Solankoa, L.; Sokola, E.; Garvikb, O.; Li, Z.; Bittmanc, R.; Korted, T.; Herrmannd, A. Chem. Phys. Lip. 2011, 164, 221. (f) Dumas-Verdes, C; Miomandre, F.; Lépicier, E.; Galangau, O.; Vu, T. V.; Clavier, G.; Méallet-Renault, R.; Audebert, P. Eur. J. Org. Chem. 2010, 2525.(g) Lazarides, T.; McCormick, T. M.; Wilson, K. C.; Lee, S.; McCamant D. W.; Eisenberg, R. J. Am. Chem. Soc. 2011, 133, 350. (h) Dodani, S. C.; Leary, S. C., Cobine, P. A.; Winge, D. N.; Chang, C. J. J. Am. Chem. Soc., 2011, 133, 8606. (i) Ehrenschwender, T.; Wagenknecht, H-A J. Org. Chem. 2011, 76, 2301. (j) Liras, M.; García, O.; Quijada-Garrido, I.; París, R. Macromolecules 2011, 44, 1335. (k) Kim, T-I.; Park, J.; Park, S.; Choi, Y.; Kim, Y. Chem. Commun. 2011, 47, 12640. (1) Whited, M. T.; Patel, N. M.; Roberts, S. T.; Allen, K.; Djurovich, P. I.; Bradforth, S. E.; Thompson, M. E. Chem. Commun. 2012, 48, 284. (m) Murale, D. P.; Lee, K. M.; Kima, K.; Churchill, D. G. Chem. Commun. 2011, 47, 12512. (n) Baruah, M.; Qin, W.; Basaric, N.; De Borggraeve, W. M.; Boens, N. J. Org. Chem. 2005, 70, 4152. (o) Chen, Y.; Zhao, J.; Guo, H.; Xie, L. J. Org. Chem. 2012, 77, 2192. (p) Matsumoto, T.; Urano, Y.; Shoda, T.; Kojima, H.; Nagano, T. Org. Lett. 2007, 9, 3375. (q) Kamiya, M.; Johnsson, K. Anal. Chem., 2010, 82, 6472. (r) Lee, C-H.; Yoon, H-J.; Shim, J-S.; Jang, W-D Chem. Eur. J. 2012, 18, 4513. (s) Lu, H.; Zhang, S.; Liu, H.; Wang, Y.; Shen, Z.; Liu, C.; You, X. J. Phys. Chem. A 2009, 113, 14081. (t) Rosenthal, J.; Lippard, S. J. J. Am. Chem. Soc. 2010, 132, 5536. (u) Nierth, A.; Kobitski, A. Y.; Nienhaus, G. U.; Jäschke, A. J. Am. Chem. Soc. 2010, 132, 2646. (v) Bozdemir' O. A.; Sozmen, F.; Buyukcakir, O.; Guliyev, R.; Cakmak, Y.; Akkaya, E. U. Org. Lett. , 12, 1400. (w) Dodani, S.C.; He, Q.; Chang, C. J. J. Am. Chem. Soc. **2009**, 131, 18020. (x) Saito, R.; Ohno, A.; Ito, E. Tetrahedron 2010, 66, 583. (y) Peña, B.; Barhoumi, R.; Burghardt, R. C.; Turro, C.; Dunbar, K. R. J. Am. Chem. Soc. , *136*, 7861.

- (19) Peña-Cabrera, E.; Aguilar-Aguilar, A.; Gonzalez-Dominguez, M.; Lager, E.; Zamudio-Vazquez, R.; Godoy-Vargas, J.; Villanueva-García, F. Org. Lett. 2007, 9, 3985.
- (20) (a) H. Prokopcová, H.; Kappe, C. O. Angew. Chem. Int. Ed. 2008, 47, 3674. (b) Prokopcová; H.; Kappe, C. O. Angew. Chem. Int. Ed. 2009, 48, 2276.
- (21) Goud, T. V.; Tutar, A.; Biellmann, J.-F. Tetrahedron 2006, 62, 5084.
- (22) Wagner, R. W.; Lindsey, J. S. Pure & Appl. Chem. 1996, 68, 1373.
- (23) (a) Lager, E.; Liu, J.; Aguilar-Aguilar, A.; Tang, B. Z.; Peña-Cabrera, E. J. Org. Chem. 2009, 74, 2053. (b) Arroyo, I. J.; Hu, R.; Tang, B. Z.; López, F. I.; Peña-Cabrera, E. Tetrahedron 2011, 67, 7244.
- (24) Arroyo, I. J.; Hu, R.; Merino, G.; Tang, B. Z.; Peña-Cabrera, E. J. Org. Chem. **2009**, 74, 5719.
- (25) (a) Esnal, I.; Urías-Benavides, A.; Gómez-Durán, C. F. A.; Osorio-Martínez, C. A.; García-Moreno, I.; Costela, A.; Bañuelos, J.; Epelde, N.; López Arbeloa, I.; Hu, R.; Tang, B. Z.; Peña-Cabrera, E. *Chem. Asian J.* 2013, *8*, 2691.
- (26) Flores-Rizo, J. O.; Esnal, I.; Osorio-Martínez, C. A.; Gómez-Durán, C. F. A.; Bañuelos, J.; López Arbeloa, I.; Pannell, K. H.; Metta-Magaña, A. J.; Peña-Cabrera, E. J. Org. Chem. 2013, 78, 5867.

	1	
	2	
	_	
	2	
	3	
	,	
	4	
1	5	
	J	
	~	
	h	
	~	
	7	
	1	
	~	
i	В	
	-	
	a	
,	J	
	1	Λ
	L	υ
	1	1
	•	
	1	S
	L	Ζ
		~
	1	З
		~
	1	Λ
	I.	4
		-
	1	5
		Ū
	1	ิค
	1	o
	4	~
	1	1
	į	-
	1	R
	1	J
	4	\sim
	1	Э
	Ĵ	
	2	n
	<u> </u>	J
	0	4
	2	1
	_	-
	2	2
	ć	-
	0	2
	2	J
	_	
1	2	4
	<u> </u>	-
	n	F
	2	Э
	_	~
1	2	6
	-	0
	n	7
	2	1
	_	_
1	2	8
	-	0
	n	o
	2	3
	\sim	~
1	3	0
;	3	0
;	3 2	0 1
	3 3	0 1
	33	01
	3 3 3	0 1 2
	3 3 3	0 1 2
	3 3 3 3	0 1 2 3
	3 3 3 3	0 1 2 3
	3 3 3 3	0 1 2 3
	3 3 3 3 3	0 1 2 3 4
	3 3 3 3 3 3	0 1 2 3 4
	3 3 3 3 3 3 3	0 1 2 3 4 5
	3 3 3 3 3 3	0 1 2 3 4 5
	3 3 3 3 3 3 3 3	0 1 2 3 4 5 6
	3 3 3 3 3 3 3 3	0 1 2 3 4 5 6
		0123456
	33333333	01234567
	3 3 3 3 3 3 3 3 3 3 3 3	01234567
	3333333333	012345678
	3 3 3 3 3 3 3 3 3 3 3 3	012345678
		0123456780
	3 3 3 3 3 3 3 3 3 3 3 3 3 3	0123456789
	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	01234567896
	33333333333	01234567890
	33333333334	01234567890
	333333333344	012345678901
	333333333344	012345678901
	333333333444	0123456789012
	3333333333444	0123456789012
	33333333334444	01234567890126
	33333333334444	01234567890123
	3 3 3 3 3 3 3 3 3 4 4 4 4 4	01234567890123
	3 3 3 3 3 3 3 3 3 4 4 4 4	012345678901234
	33333333444444444444444444444444444444	012345678901234
		0123456789012345
	3 3 3 3 3 3 3 3 3 4 4 4 4 4 4	0123456789012345
	33333333444444	0123456789012345
	3333333334444444	01234567890123456
	333333333344444444	01234567890123456
	333333333444444444	012345678901234567
	3333333334444444444444444444444444444	012345678901234567
	333333334444444444444444444444444444444	0123456789012345676
	3333333333444444444444444444444444444	0123456789012345678
	33333333444444444	0123456789012345678
	3333333333444444444444444444444444444	01234567890123456789
	3333333333444444444444444444444444444	01234567890123456789
	333333333444444444444444444444444444444	012345678901234567890
	333333333444444444444444444444444444444	012345678901234567890
	33333333344444444444	012345678901234567890
	3333333334444444444455	0123456789012345678901
	33333333344444444444	0123456789012345678901
	33333333344444444444555	01234567890123456789012
	33333333344444444444555	01234567890123456789012
	33333333344444444445555	012345678901234567890123
	3333333334444444444455555	012345678901234567890123
	3333333334444444444455555	012345678901234567890123
	333333333444444444445555555	0123456789012345678901234
	3333333334444444444555555	0123456789012345678901234
	33333333344444444445555555	01234567890123456789012345
	33333333344444444445555555	01234567890123456789012345
	333333333444444444455555555555555555555	012345678901234567890123456
	33333333334444444444555555555	012345678901234567890123456
	333333333344444444445555555555555555555	0123456789012345678901234567
	333333333344444444445555555555555555555	0123456789012345678901234567
	333333333344444444455555555555555555555	0123456789012345678901234567
	333333333344444444445555555555555555555	01234567890123456789012345678
	333333333344444444455555555555555555555	01234567890123456789012345678
	333333333344444444455555555555555555555	012345678901234567890123456782

(27) Gutiérrez-Ramos, B. D.; Bañuelos, J.; Arbeloa, T.; López Arbeloa, I.; González-Navarro, P. E.; Wrobel, K.; Cerdán, L.; García-Moreno, I.; Costela, A.; Peña-Cabrera, E. *Chemistry Eur. J.* 2015, *21*, 1755.

- (28) Martinez-Gonzalez, M. R.; Urías-Benavides, A.; Alvarado-Martínez, E.; Lopez, J. C.; Gómez, A. M.; del Rio, M.; Garcia, I.; Costela, A.; Bañuelos, J.; Arbeloa, T.; Lopez Arbeloa, I.; Peña-Cabrera, E. *Eur. J. Org. Chem.* **2014**, *26*, 5659.
- (29) Kinzel, T.; Zhang, Y.; Buchwald, S. L. J. Am. Chem. Soc. 2010, 132, 14073.
- (30) (a) Gräf, K.; Körzdörfer, T.; Kümmel, S.; Thelakkat, M. New J. Chem., 2013, 37, 1417. (b) Barin, G.; Yilmaz, M. D.; Akkaya, E. U. Tetrahedron Lett. 2009, 50, 1738. (c) Erten-Ela, S.; Yilmaz, M., D.; Icli, B.; Dede, Y.; Icli, S.; Akkaya, E. U. Org. Lett. 2008, 10, 3299.
- (31) Yue, Y.; Guo, Y.; Xua, J.; Shao, S. New J. Chem. 2011, 35, 61.
- (32) Roacho, R. I.; Metta-Magaña, A.; Peña-Cabrera, E.; Pannell, K. Org. Biomol. Chem. 2015, 13, 995.
- (33) (a) Egi, M.; Liebeskind, L. S. Org. Lett. 2003, 5, 801. (b) Li, H.; Yang, H.; Liebeskind, L. S. Org. Lett. 2008, 10, 4375.
- (34) Mee, S. P. H.; Lee, V.; Baldwin, J. E. Angew. Chem. Int. Ed. 2004, 43, 1132.
- (35) Alphonse, F.-A.; Suzenet, F.; Keromnes, A.; Lebret, B.; Guillaumet, G. Org. Lett. 2003, 5, 803.
- (36) Duran-Sampedro, G.; Agarrabeitia, A. R.; Garcia-Moreno, I.; Costela, A.; Bañuelos, J.; Arbeloa, T.; López Arbeloa, I.; Chiara, J. L.; Ortiz, M. J. *Eur. J. Org. Chem.* **2012**, 6335.
- (37) Gibbs, J.H.; Robins, L. T.; Zhou, Z.; Bobadova-Parvanova, P.; Cottam, M.; McCandless, G. T.; Fronczek, F. R.; Vicente, M. G.H. *Bioorg. Med. Chem.* 2013, 21, 5770.
- (38) (a) Kuimova, M. K.; Botchway, S. W.; Parker, A. W.; Balaz, M.; Collins, H. A.; Anderson, H. L.; Suhling, K.; Ogilby, P. R. *Nat. Chem.* 2009, *1*, 69. (b) Kuimova, M. K.; Yahioglu, G.; Levitt, J. A.; Suhling, K. *J. Am. Chem. Soc.* 2008, *130*, 6672. (c) Alamiry, M. A. H.; Benniston, A. C.; Copley, G.; Elliot, K. J.; Harriman, A.; Stewart, B.; Zhi, Y.-G. *Chem. Mater.* 2008, *20*, 4024.
- (39) Swamy. P., C. A.; Thilagar, P. Inorg. Chim. Acta 2014, 411, 97.
- (40) Cui, A.; Peng , X.; Fan, J.; Chen, X.; Wu, Y.; Guo, B. J. Photochem. *Photobiol.A* **2007**, *186*, 85.
- (41) Roacho, R. I.; Metta-Magaña, A. J.; Peña-Cabrera, E.; Pannell, K. H. J. *Phys.Org. Chem.* **2013**, *26*, 345.

TOC



Advantages:

- 1) The Biellmann BODIPYs are commercially available
- 2) Neutral and mild reaction conditions
- 3) Operationally simple
- 4) High functional group tolerance
- 5) Convergent